溶瘤病毒
彭布罗利珠单抗
肿瘤微环境
免疫检查点
医学
癌症免疫疗法
免疫系统
癌症
免疫疗法
免疫学
肿瘤科
内科学
作者
Matthew Chiu,Edward John Lloyd Armstrong,Vicki Jennings,Shane Foo,Eva Crespo-Rodriguez,Galabina Bozhanova,Emmanuel C. Patin,Martin McLaughlin,David Mansfield,Gabriella Baker,Lorna Grove,Malin Pedersen,Joan Kyula,Victoria Roulstone,Anna Wilkins,Fiona McDonald,Kevin J. Harrington,Alan Melcher
标识
DOI:10.1080/14712598.2020.1729351
摘要
Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to some tumors cultivating an inherently ‘cold’ immune microenvironment. Oncolytic viruses (OV) have the capability to promote a ‘hotter’ immune microenvironment which can improve the efficacy of ICI.Areas covered: In this article we conducted a literature search through Pubmed/Medline to identify relevant articles in both the pre-clinical and clinical settings for combining OVs with ICIs and discuss the impact of this approach on treatment as well as changes within the tumor microenvironment. We also explore the future directions of this novel combination strategy.Expert opinion: The imminent results of the Phase 3 study combining pembrolizumab with or without T-Vec injection are eagerly awaited. OV/ICI combinations remain one of the most promising avenues to explore in the success of cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI